Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Cystoid macular edema (CME) is a common complication after cataract extraction.
• Refractory pseudophakic CME poses a significant challenge to visual function.
• Current treatment modalities for pseudophakic CME may not be sufficient for all patients.

Purpose of the Study:

• To evaluate the safety and efficacy of intravitreal triamcinolone acetonide (TAAC) injections.
• To assess TAAC's impact on visual acuity and macular edema in pseudophakic patients.
• To determine the role of TAAC in managing refractory CME post-cataract surgery.

Main Methods:

• Retrospective case review of 8 eyes with pseudophakic CME.
• Intravitreal injection of 1 mg triamcinolone acetonide (TAAC).
• Follow-up included visual acuity, biomicroscopy, angiography, intraocular pressure (IOP) monitoring, and complication assessment.

Main Results:

• All patients experienced improved visual acuity and angiographic evidence of reduced perifoveal leakage.
• Temporary IOP elevation was manageable with topical medications; no other adverse effects were noted.
• Efficacy was influenced by underlying macular pathology and baseline visual acuity; repeated injections were required.

Conclusions:

• Intravitreal TAAC is a safe and effective treatment for recalcitrant pseudophakic CME.
• TAAC demonstrates a beneficial effect on macular edema and visual acuity.
• Further randomized studies are needed to optimize TAAC use, and sustained-release systems may be advantageous.